<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ATryn(Â®) is a transgenically produced recombinant antithrombin (AT) concentrate licensed in Europe and the USA for the thromboprophylaxis of hereditary AT-deficient patients undergoing surgical procedures who are at a high risk of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is also licensed, in the USA only, for prevention the of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in association with delivery and the immediate post-partum period </plain></SENT>
<SENT sid="2" pm="."><plain>ATryn is administered as a continuous intravenous infusion, with weight-adjusted loading and maintenance dosing regimens </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant AT has an identical amino acid structure with minor glycosylation differences to endogenous AT </plain></SENT>
<SENT sid="4" pm="."><plain>ATryn has a shorter half-life but an equivalent efficacy to that of plasma-derived AT concentrates in the prevention of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in this rare distinct group with a high thrombotic risk </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, this recombinant product should be free from the risk of human <z:mp ids='MP_0001799'>viral</z:mp> or prion transmission </plain></SENT>
</text></document>